Enjoy complimentary customisation on priority with our Enterprise License!
The pruritus drugs market size is forecast to increase by USD 5.9 billion at a CAGR of 7.1% between 2023 and 2028. The market is witnessing significant growth due to the increasing prevalence of itchiness and skin-related conditions. The symptoms of pruritus, including intense itchiness and discomfort, can significantly impact an individual's quality of life. Underlying medical conditions, such as liver diseases, kidney disorders, and cancer, can cause pruritus, making its medical diagnosis and treatment crucial. The market is driven by the growing preference for effective relief from pruritus symptoms. Immunotherapy, a novel treatment option, is gaining popularity due to its ability to modulate the immune response and provide long-term relief. Additionally, the emergence of alternative therapies, such as phototherapy and acupuncture, offers patients more choices for managing their condition. However, the market faces challenges, including the difficulty in accurately diagnosing the underlying cause of pruritus and the potential for medication side effects. Irritants, such as certain foods and chemicals, can also trigger pruritus symptoms, making prevention an essential aspect of treatment. Overall, the market is expected to grow as researchers continue to develop new and effective treatment options for this debilitating condition.
Pruritus can be a symptom of various underlying medical conditions, including allergies, eczema, psoriasis, diabetes, dialysis, and certain irritants. In some cases, it may be associated with senile pruritus, brachioradial pruritus, nocturnal pruritus, or pruritus ani. Irritants, such as dry skin, inflammation, skin discoloration, rash, papules, and blisters, can also trigger pruritus. The symptoms of pruritus can range from mild to severe, and the condition can lead to scratching, which can further aggravate the skin and cause damage. In some cases, the itching may be worse at night, leading to sleep disturbances and fatigue.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The hematologic pruritus segment is estimated to witness significant growth during the forecast period. Hematologic pruritus, a type of pruritus, is primarily caused by various underlying medical conditions, including iron deficiency anemia. This condition is characterized by itchiness, often localized to the perianal and vulvar regions. Iron is essential for numerous enzymic activities in the body, and any imbalance in iron levels can lead to pruritus. Iron deficiency is also associated with other hematologic pruritus indications, such as glossitis and angular cheilitis, which cause inflammation in the tongue and mouth.
Get a glance at the market share of various segments Download the PDF Sample
The hematologic pruritus segment was the largest segment and was valued at USD 3.10 billion in 2018. These conditions can persist for an extended period, ranging from days to years. Medication is an effective treatment for pruritus caused by underlying medical conditions. Several medications, including antihistamines, opioid antagonists, and corticosteroids, are used to provide relief from the symptoms of pruritus. It is crucial to diagnose the underlying medical condition to determine the most effective medication for treatment. Prevention of pruritus involves addressing the underlying medical condition. For iron deficiency anemia, dietary modifications, such as consuming iron-rich foods or iron supplements, can help prevent pruritus. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is poised for substantial expansion during the forecast period, fueled by the high incidence of underlying conditions causing pruritus. Pruritus, characterized by an intense itch, can be attributed to various causes such as diabetes, dialysis, dry skin, inflammation, skin discoloration, rash, papules, and blisters. In North America, the presence of a strong healthcare system and the presence of numerous pharmaceutical companies with a strong focus on research and development for innovative therapies contribute to the region's market growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing preference for immunotherapy is notably driving market growth. The global market is experiencing notable expansion due to the increasing prevalence of various conditions causing itching. Pruritus, also known as itching, can be caused by systemic diseases such as neuropathic, psychogenic, environmental factors, seasonal allergies like hay fever and asthma, chronic conditions including HIV/AIDS and kidney disease, and other causes.
Immunotherapy drugs have emerged as a significant factor driving market growth. These drugs, used in the treatment of various chronic conditions, have seen considerable advancements in recent years. For instance, the oncology therapeutics sector has witnessed substantial progress, with the approval of novel targeted therapies like EGFR inhibitors, VEGF inhibitors, and PD-1 inhibitors for the treatment of various cancer indications. Thus, such factors are driving the growth of the market during the forecast period.
Emergence of novel treatment options is the key trend in the market. The urge to scratch, while a natural response to remove irritants, can lead to rashes, scratch marks, cracked skin, scaly patches, and discolored skin. Chronic itching, however, poses a clinical challenge as the underlying causes remain elusive. The emergence of TRP (Transient Receptor Potential) channels has shed light on the itching mechanism.
TRP channels, a family of six trans-membrane cation channels, were initially identified in Drosophila for their role in phototransduction. In humans, there are 27 TRP family members, categorized into six subgroups based on homology. These channels play a crucial role in sensing various stimuli, including temperature, pain, and itch. The itching market, though understudied, holds significant potential for the development of efficacious drugs that can target the root cause. Thus, such trends will shape the growth of the market during the forecast period.
Availability of alternative therapies is the major challenge that affects the growth of the market. Pruritus, or chronic itching, is a prevalent condition affecting various populations, including those with liver disease, thyroid disorders, anemia, and cancer. The symptoms of pruritus can range from mild itching and scratching to severe pain, tingling, and red or inflamed skin.
While there are numerous approved drugs for pruritus treatment, the preventive nature of pruritus in certain conditions poses a challenge to market growth. For instance, hematological pruritus, often caused by iron deficiency, can be managed through iron supplements like ferrous sulfate. However, the focus on preventive measures and alternative therapies, such as lifestyle modifications and herbal remedies, may hinder the market expansion. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc: The company offers pruritus drugs under the brand name of Teflaro.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market caters to the growing demand for effective treatments for various forms of itching, a common symptom affecting the skin. Itching, or pruritus, can be a result of underlying medical conditions, irritants, or allergies. The symptoms can range from mild to severe and may lead to discomfort, pain, and even psychological distress. Dermatology plays a crucial role in diagnosing and treating pruritus, as it can be a symptom of various skin conditions such as eczema, psoriasis, diabetes, dialysis, dry skin, and inflammation. Skin discoloration, rashes, papules, blisters, and nerve endings can also be indicative of pruritus. Neuropathic, psychogenic, environmental, and seasonal allergies, including brachioradial pruritus, nocturnal pruritus, pruritus ani, senile pruritus, uremic pruritus, and allergies to hay fever, asthma, and chronic conditions like HIV/AIDS, kidney disease, liver disease, thyroid disease, anemia, and cancer, can cause itching. Medications and treatments are available to provide relief from pruritus symptoms. These include topical and systemic medications, peripheral sensory neuron modulators, and environmental modifications. The prognosis for pruritus depends on the underlying cause and timely diagnosis and treatment. Prevention measures include avoiding irritants and maintaining good skin hygiene.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
157 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.1% |
|
Market growth 2024-2028 |
USD 5.9 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.3 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, UK, Germany, China, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Almirall SA, Astellas Pharma Inc., Bristol Myers Squibb Co., Cara Therapeutics Inc., Cipla Inc., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Ipca Laboratories, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Sanofi SA, and Sun Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, market report , market forecast , Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
